Palatin Technologies (PTN) Retained Earnings (2011 - 2026)
Palatin Technologies' (PTN) quarterly Retained Earnings came in at $473.7 million in Q1 2026, up 203.68% on a YoY basis from $156.0 million in Q1 2025, and little changed quarter-over-quarter from $473.1 million in Q4 2025.
Analysis
Palatin Technologies (PTN) Retained Earnings (2011 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Retained Earnings for 15 consecutive years, with $473.7 million the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 203.68% year-over-year to $473.7 million; the trailing twelve-month figure through Mar 2026 stood at $473.7 million (up 203.68% YoY), and the FY2025 full-year result was -$459.1 million, down 3.92% from the prior year.
- Retained Earnings steadied at $473.7 million in Q1 2026 per PTN's latest filing, from $473.1 million in the prior quarter.
- Across five years, Retained Earnings topped out at $473.7 million in Q1 2026 and bottomed at -$459.1 million in Q2 2025.
- Historically, Retained Earnings has averaged $21.0 million across 5 years, with a median of $401.0 million in 2022.
- The widest YoY moves for Retained Earnings: up 204.66% in 2025, down 205.04% in 2025.
- Over 5 years, Retained Earnings stood at $413.9 million in 2022, then tumbled by 202.7% to -$425.1 million in 2023, then fell by 6.34% to -$452.0 million in 2024, then surged by 204.66% to $473.1 million in 2025, then advanced by 0.12% to $473.7 million in 2026.
- According to Business Quant data, Retained Earnings over the past three periods registered $473.7 million, $473.1 million, and $454.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | -22.28 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 9.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 15.69 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 37.62 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 558.00 Mn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | -6.33 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 20.97 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 5.13 Bn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - | 473.67 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 473.67 Mn |
| Dec 31, 2025 | 473.11 Mn |
| Sep 30, 2025 | 454.78 Mn |
| Jun 30, 2025 | -459.07 Mn |
| Mar 31, 2025 | -456.84 Mn |
| Dec 31, 2024 | -452.03 Mn |
| Sep 30, 2024 | -449.59 Mn |
| Jun 30, 2024 | -441.77 Mn |
| Mar 31, 2024 | 434.93 Mn |
| Dec 31, 2023 | -425.08 Mn |
| Sep 30, 2023 | -421.38 Mn |
| Jun 30, 2023 | -412.03 Mn |
| Mar 31, 2023 | 414.30 Mn |
| Dec 31, 2022 | 413.91 Mn |
| Sep 30, 2022 | 404.61 Mn |
| Jun 30, 2022 | 404.17 Mn |
| Mar 31, 2022 | 400.99 Mn |
| Dec 31, 2021 | 400.47 Mn |
| Sep 30, 2021 | 399.56 Mn |
| Jun 30, 2021 | 401.35 Mn |